NASDAQ · PACB

Pacific Biosciences of California, Inc.

Healthcare · Medical - Devices

$1.39▲ 3.36% ($0.05)today

As of 11:22 AM ET

52-week

$1.07$2.73

Market cap

$430.18M

What the market price implies · Reverse DCF

Historical revenue grew by 5.23%/yr over the past 4 years.

Selected forecast · Base scenario

1.54%/yr · actual 10-year annualized revenue growth

Year 1 growth: 2.4%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$1.39

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Enterprise value of $29.25M does not cover net debt of $407.46M, so equity value is negative and no fair value per share can be shown. 6 of 10 projected years carry negative free cash flow. This engine cannot separate captive-finance or other non-operating borrowings from operating debt.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 2.4% · Ending margin 0% · Discount rate 7.57%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 3:22 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 17, 2026, 3:22 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 12.6%Revenue (TTM): 2.02%FCF (TTM): -8.8%P/S: 15th pct

What changed

The stock rose 12.6% over the last year. Revenue grew 2.02% over the trailing twelve months. Operating margin moved from -442.57% to -102.05%. Free cash flow declined 8.8% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -102.05%. A decisive move in revenue — currently up 2.02% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges.

CEOMark Van Oene

SectorHealthcare

IndustryMedical - Devices

Employees485

IPO dateOct 27, 2010

https://www.pacb.com

Market multiples

Forward P/E—

EV/EBITDA-36.76

Enterprise value$1.26B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-1.91%

Gross margin (FY2025)31.67%▲7.5ppvs FY2024

Operating margin (FY2025)-348.46%▼40.5ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$1.18▼14.80%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est -$0.13 · Revenue est $43.82M

View